Rating (action)
ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma
ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile
Pfizer and Sangamo’s Gene Therapy Shows Superiority Over Prophylaxis in Hemophilia A Study
Pfizer, Sangamo, gene therapy, hemophilia A, prophylaxis, giroctocogene fitelparvovec, bleeding rate, Factor VIII
Pfizer’s Hemophilia A Gene Therapy Candidate Achieves Phase 3 Success
Pfizer, Hemophilia A, Gene Therapy, Phase 3 Trial, Giroctocogene Fitelparvovec, Bleeding Rate Reduction
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency
AstraZeneca’s Ultomiris Gains FDA Approval for Rare Autoimmune Condition – NMOSD
AstraZeneca, Ultomiris, ravulizumab-cwvz, FDA Approval, Rare Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Long-acting C5 complement inhibitor, Phase 3 CHAMPION-NMOSD Trial, Reduced Relapse Rate, Dosing Frequency